Longboard Pharmaceuticals
Clinical trials sponsored by Longboard Pharmaceuticals, explained in plain language.
-
New hope for Hard-to-Treat seizures: phase 3 trial launches
Disease control Recruiting nowThis study tests an experimental drug called LP352 to see if it can safely reduce seizures in children and adults with developmental and epileptic encephalopathies (DEE), a group of severe epilepsy syndromes. About 320 participants will receive either LP352 or a placebo, and rese…
Phase: PHASE3 • Sponsor: Longboard Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New hope for dravet syndrome: phase 3 trial of LP352 aims to cut seizure frequency
Disease control Recruiting nowThis study tests whether the drug LP352 can safely reduce seizures in children and adults with Dravet syndrome, a severe form of epilepsy. About 160 participants will receive either LP352 or a placebo, and researchers will track changes in seizure frequency over several months. T…
Phase: PHASE3 • Sponsor: Longboard Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC